论文部分内容阅读
粒-巨噬细胞集落刺激因子(GM-CSF)可用于防治化疗后白细胞减少。在体外培养中它还具有促进红系细胞生成的作用,但对接受细胞毒药物化疗的恶性肿瘤患者体内红系细胞作用的报道尚不多见。本文通过测定实体瘤化疗患者应用GM-CSF后网织红细胞、血红蛋白(Hb)和红细胞比积(HCT)的变化,提示GM-CSF对体内红系生成具有一定的促进作用。 34名可供研究的患者随机分为两组,其中实验组在每个化疗周期第8天和第15天给予GM-CSF,300u/d,以预防白细胞减少,对照组则未接受GM-CSF。实体瘤共有非小细胞型肺癌(6例)、小细胞型肺癌(6例)、卵
Granulocyte-macrophage colony-stimulating factor (GM-CSF) can be used to prevent leukopenia after chemotherapy. It also has the effect of promoting the formation of erythroid cells in vitro culture, but reports on the role of erythroid cells in malignant tumor patients undergoing chemotherapy with cytotoxic drugs are rare. This article measured the changes of reticulocyte, hemoglobin (Hb) and hematocrit (HCT) after GM-CSF treatment in patients with solid tumors, suggesting that GM-CSF has a certain role in promoting the formation of erythroid in vivo. Thirty-four patients available for study were randomly divided into two groups. The experimental group received GM-CSF on day 8 and day 15 of each chemotherapy cycle at 300 μg/d to prevent leukopenia, whereas the control group did not receive GM-CSF. . There were non-small cell lung cancer (6 cases), small cell lung cancer (6 cases), and eggs.